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a  b  s  t  r  a  c  t
This work  proposes  the  design  of  nanoparticles  based  on locus  bean  gum  (LBG)  and  chitosan  to  be
used  as  oral  immunoadjuvant  for vaccination  purposes.  LBG-based  nanoparticles  were  prepared  by  mild
polyelectrolyte  complexation  between  chitosan  (CS) and  a synthesized  LBG  sulfate  derivative  (LBGS).
Morphological  characterization  suggested  that  nanoparticles  present  a solid  and compact  structure  with
spherical-like  shape.  Sizes  around  180–200  nm  and  a positive  surface  charge  between  +9  mV and  +14  mV
were  obtained.  CS/LBGS  nanoparticles  did  not  affect  cell  viability  of  Caco-2  cells  after  3  h and  24  h  of
exposure  when  tested  at concentrations  up to 1.0  mg/mL.  Two  model  antigens  (a  particulate  acellular
extract  HE  of Salmonella  enterica  serovar  Enteritidis,  and  ovalbumin  as  soluble  antigen)  were  associated
to  CS/LBGS  nanoparticles  with  efficiencies  around  26% for  ovalbumin  and 32%  for  HE,  which  resultedolymeric nanoparticles in  loading  capacities  up to 12%.  The  process  did not  affect  the  antigenicity  of  the associated  antigens.
BALB/c  mice  were  orally  immunized  with  ovalbumin-loaded  nanoparticles  (100  g),  and  results  indicate
an  adjuvant  effect  of  the  CS/LBGS  nanoparticles,  eliciting  a balanced  Th1/Th2  immune  response.  Thus,
CS/LBGS  nanoparticles  are promising  as  antigen  mucosal  delivery  strategy,  with  particular  interest  for
oral administration.
© 2017  Elsevier  B.V.  All  rights  reserved.. Introduction
The search for alternative vaccination approaches that may  cir-
umvent the limitations of parenteral delivery is not new. Mucosal
accination has, thus, been gaining popularity in the recent decades
nd some mucosal vaccines are currently available in the market
1,2]. The oral route is the one gathering higher interest concern-
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∗∗ Corresponding author at: INEB, Instituto de Engenharia Biomédica, Biocarrier
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B. Sarmento).
ttp://dx.doi.org/10.1016/j.ijbiomac.2016.12.076
141-8130/© 2017 Elsevier B.V. All rights reserved.ing this alternative vaccination concept, not only because of the
general advantages associated with oral administration, but also
due to relevant features of the intestine for immunization. In this
regard, a special mention is due to the gut associated mucosal tissue
(GALT), which has sites where immune responses are initiated and
effector sites where adaptive immune responses are executed [2].
The Peyer’s patches existing in the GALT comprise the main loca-
tion of immune cells associated to the intestinal mucosa [3] and
are separated from the intestinal lumen by the follicle associated
epithelium (FAE) [4]. The FAE is composed of enterocytes, goblet
cells and microfold cells (M cells) [3,5], the latter being reported to
have a thinner mucus layer, and good ability for antigen uptake and
transport to antigen presenting cells (APCs) [6]. Apart from these
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rimary access for most human pathogens [7], mainly through the
outh. As mucosal immunization is expected to elicit both sys-
emic and mucosal immunity, the development of the latter at the
ntestinal level becomes a relevant tool towards limiting or pre-
enting pathogen entry, thus inhibiting the consequent infection
8,9].
Notwithstanding the evident ability of the intestinal area for
ntigen recognition, antigens are biopharmaceuticals, thus being
ighly sensitive molecules that require specific precautions regard-
ng their formulation and delivery. Indeed, the protein-based
tructure hinders the possibility of a direct oral administration,
ainly because of the low gastric pH and the high content of
roteases [10,11]. Suitable particles are therefore demanded for
 successful oral immunization approach and nanoparticles have
een indicated many times as very useful in mediating this pro-
ess. Apart from providing the associated antigens with protection
rom the harsh gastrointestinal conditions referred above, their
mall size might permit an intimate contact with the epithelial
urface, where cells with relevant roles in the generation of an
mmune response are located [12]. In addition, nanoparticles may
lso act as immunomodulator adjuvants, meaning that the parti-
le itself mediate the development of the immune response. Thus,
he particles may  facilitate both the antigen uptake and internal-
zation by GALT and, also, the antigenic cross-presentation by APCs
13]. The use of particle vehicles exhibiting targeting moieties that
ave a favoured interaction with epithelial glycoconjugates that
re specifically activated by pathogens, such as the toll-like recep-
or (TLR) family or the mannose receptor, has been proposed as a
trategy that mimics microbial behaviour in the development of
mmune responses [13].
The uptake of particles is reported to primarily occur via the
 cells [2], which have been referred to provide a privileged con-
act with mannose residues [14,15] and, therefore, might be used
s privileged target for mannose-containing particles. Locust bean
um (LBG) is a polysaccharide of the class of galactomannans, thus
aving a chemical structure composed of both galactose and man-
ose units [16] (Fig. 1). Therefore, it potentially has the ability to
rovide the said favoured contact between nanoparticles and the
 cells. The use of mucoadhesive polymers, such as chitosan, may
lso benefit the contact of nanoparticles with epithelial surfaces,
wing to the prolonged retention time provided by mucoadhesion.
On the other hand, inactivated vaccines, including the subunit
nes, are gathering higher interest, not only due to the general
dvantages over the living vaccines, but also because they per-
it  an easier chain of distribution, as a cold-chain is not necessary
17], which is relevant for developing countries [18,19]. Thus, the
esign of nanoparticles based on LBG and chitosan to be used
s antigen delivery systems for oral immunization purposes is
resented herein. A negatively charged derivative of LBG was pro-
uced (sulfated LBG) to enable the production of nanoparticles by
olyelectrolyte complexation. Two different model antigens were
ssociated to the nanoparticles, a liposome-like antigenic complex
f Salmonella enterica serovar Enteritidis [20] and ovalbumin, a
ell-known soluble antigen, in order to carry out immunogenic
tudies in mice.
. Materials and methods
.1. Materials
Ultrapure chitosan (CS) in the form of hydrochloride salt
Protasan
®
UP Cl 113, deacetylation degree = 75%–90%, molecu-
ar weight <200 kDa), was purchased from Pronova Biopolymer
Sandvika, Norway). Locust bean gum (LBG) was  a kind gift from
ndustrial Farense (Faro, Portugal). Immunogenic acellular extractal Macromolecules 96 (2017) 786–797 787
obtained from whole Salmonella Enteritidis cells (HE) was prepared
according to a previously described method [21]. Ovalbumin (OVA),
bovine serum albumin (BSA), phosphotungstate dibasic hydrate,
glycerol, phosphate buffered saline (PBS) pH 7.4 tablets, Dul-
becco’s modified Eagle’s medium (DMEM), penicillin/streptomycin
(10,000 units/mL, 10000 g/mL), non-essential amino acids, L-
glutamine 200 mM,  trypsin-EDTA solution (2.5 g/L trypsin, 0.5 g/L
EDTA), trypan blue solution (0.4%), thiazolyl blue tetrazolium bro-
mide (MTT), lactate dehydrogenase (LDH) kit, sodium dodecyl
sulfate (SDS), Ponceau S red staining solution, protease inhibitor
cocktail, dimethyl sulfoxide (DMSO), HCl 37%, H2O2, 4-chloro-
1-naphtol, NaCl, KH2PO4, dialysis tubing (pore size 2000 Da),
HClSO3, dimethylformamide (DMF) and NaOH were purchased
from Sigma-Aldrich (Germany). XT sample buffer, Criterion XT bis-
tris gel, XT MOPS running buffer, Coomassie blue and Tris-glycine
buffer were provided by Bio-Rad (USA) and ethanol, PBS-tween
(PBS-T) and 3-ethylbenzthiazoline-6-sulfonic acid (ABTS) by VWR
(Portugal). Fetal bovine serum (FBS) was obtained from Gibco
(USA), molecular mass markers (Novex Sharp Pre-stained Protein
Standard) from Invitrogen (Germany). Peroxidase-conjugated goat
anti-mouse IgG1, IgG2a and IgA antibodies were purchased from
Nordic Immunology (Netherlands) and skimmed milk from Con-
tinente (Portugal). Ultrapure water (Mili-Q Plus, Milipore Iberica,
Madrid, Spain) was  used throughout. All other chemicals were
reagent grade.
2.2. Cell lines
The Caco-2 cell line was obtained from the American Type
Culture Collection (Rockville, USA) and used between passages
77–93. Cell cultures were grown in 75 cm2 flasks in a humidified
5% CO2/95% atmospheric air incubator at 37 ◦C. Cell culture medium
was DMEM supplemented with 10% (v/v) FBS, 1% (v/v) L-glutamine
solution, 1% (v/v) non-essential amino acids solution and 1% (v/v)
penicillin/streptomycin. Medium was changed every 2–3 days and
cells were subcultured weekly.
2.3. Animals
The in vivo experiments were performed in strict accordance
with good animal practice under the Declaration of Helsinki, the
Directive 2010/63/EU and the Portuguese Law DL  113/2013, and
in compliance with the regulations of the responsible commit-
tee of the University of Algarve (Faro, Portugal). Female BALB/c
mice (20 ± 1 g) were provided by Instituto Gulbekian de Ciência
(Portugal). The animals were starved 7 h before immunization and
only allowed free access to water. After immunization, they were
maintained with free access to food and water.
2.4. Synthesis of sulfated locust bean gum (LBGS) derivative
A previous purification step of LBG envisaged the removal of the
protein content (3–7%) commonly present in commercial samples
[22]. To do so, a standard procedure was  followed [23,24], in which
LBG (5.0 g) was slowly dispersed in deionized water (1000 mL) pre-
viously heated to 85 ◦C, the dispersion being stirred for 1 h. Then,
the dispersion was  cooled to room temperature and, subsequently,
centrifuged (22,000 × g, 20 ◦C, 1 h). The supernatant was  collected
and added to an equal volume of ethanol. The precipitate was col-
lected by vacuum filtration and added again to an equal volume of
ethanol. After subsequent collection by vacuum filtration, the pre-
cipitate was dried in a vacuum oven at 30 ◦C during 72 h affording
3.9 g of white powder. The residue was  grinded and stored until
further use.
Sulfation of LBG was performed by a method established for
the sulfation of other polysaccharides [25]. The sulfation agent,














































Fig. 1. Chemical stru
O3.DMF, was prepared by slowly dropping 5 mL  of HClSO3 into
5 mL  of stirred DMF  under cooling in an ice water bath, and con-
inuing the stirring for 1.5 h. The obtained solution was  stored in
he refrigerator until further use.
Purified LBG (500 mg)  was slowly dispersed in deionized water
100 mL)  previously heated to 85 ◦C, and the dispersion was  stirred
or 1 h. After that time, the dispersion was cooled to room temper-
ture and poured into an equal volume of ethanol. The precipitate
as collected, added to DMF  (300 mL)  and centrifuged (22 000 x g,
0 ◦C, 20 min). The precipitate was recovered and added to DMF
100 mL), resting overnight. This dispersion was then filtered and
he residue was again added to DMF  (35 mL), this new mixture
eing stirred at 60 ◦C for 30 min, in order to provide the dispersion
f LBG into the solvent. Then, the SO3.DMF  complex was added
9.3 mL)  and the mixture reacted for 4 h under magnetic stirring.
ubsequently, the mixture was cooled down to room temperature
n an ice bath, neutralized with 30% NaOH solution until precipita-
ion, and concentrated under reduced pressure at 60 ◦C to evaporate
he solvent. The residue was dissolved in deionized water (30 mL)
nd dialyzed against deionized water (5 L). The water was  changed
very 24 h and, after 3 days, the solution was concentrated under
educed pressure at 40 ◦C. Then, ethanol was added into the concen-
rated solution, in order to precipitate the solute, and the dispersion
as concentrated under reduced pressure at 40 ◦C. The previous
tep was repeated twice, and the last evaporation was  performed
ntil full evaporation of the solvent. The obtained powder was  dried
n a vacuum oven at 40 ◦C for 3 days, affording 363 mg  of brownish
owder that was  grinded and stored until further use.
.5. Production of chitosan/sulfated locust bean gum (CS/LBGS)
anoparticles
Different mass ratios of CS/LBGS were tested regarding the
reparation of nanoparticles by polyelectrolyte complexation
Table 1). The stock solution of CS, dissolved in ultrapure water,
as prepared at a final concentration of 1.0 mg/mL, while LBGS in
he same solvent was prepared at 4.0 mg/mL. The solutions were
ltered (0.45 m)  prior to use. The formulations were prepared by
lowly adding 1.8 mL  of LBGS to 1.0 mL  of CS under gentle magnetic
tirring at room temperature. Stirring was maintained for 10 min.
he concentration of CS was kept constant at 1.0 mg/mL  for the
reparation of all formulations, while that of LBGS was  modified to
btain the different ratios.
The suspensions of nanoparticles were then centrifuged in
ppendorfs with a layer of 10 L of glycerol (16,000 × g, 30 min,
5 ◦C; Thermo Scientific-Heraeus Fresco 17, Germany), in order to
acilitate the following step of ressuspension. After centrifugation,
he supernatants were discarded and nanoparticles were ressus-
ended with 200 L of ultrapure water. of locust bean gum.
2.6. Association of model antigens to CS/LBGS nanoparticles
2.6.1. Bacterial antigenic complex
An antigenic complex, HE, consisting of outer membrane vesi-
cles, was obtained from Salmonella Enteritidis [21]. Its association
was performed to the CS/LBGS 1:1.5 and 1:2 (w/w) nanoparticle
formulations, which selection was  mainly driven by the produc-
tion yield. The stock solution of the HE antigenic complex was
prepared by dispersion in ultrapure water (0.4 mg/mL) using the
ultra-sound bath during 15 min  at room temperature. The dis-
persion was filtered (Millex
®
– GV, 0.22 m low protein binding
filter, Millipore, Spain) prior to use. The HE-loaded nanoparticles
(NP-HE) were prepared using the same methodology used for the
unloaded nanoparticles, but the concentration of LBGS solutions
were adjusted using different concentrations of HE dispersions, in
order to obtain a theoretical content of HE of 2%, 4% or 8% (w/w) of
the total amount of polymers.
2.6.2. Ovalbumin
The association of OVA was performed to the CS/LBGS 1:2 (w/w)
nanoparticle formulation. The stock solution of OVA was  prepared
by dissolving it in ultrapure water (0.3 mg/mL) under magnetic
stirring during 15 min  at room temperature. The solution was
filtered (Millex
®
– GV, 0.22 m low protein binding filter, Milli-
pore, Spain) prior to use. The OVA-loaded nanoparticles (NP-OVA)
were prepared using the same methodology used for the unloaded
nanoparticles, but the concentration of LBGS solution was adjusted
using the OVA stock solution, in order to obtain a theoretical con-
tent of OVA of 8% (w/w)  of the total amount of polymers.
2.7. Characterization of CS/LBGS nanoparticles
2.7.1. Size, zeta potential and polydispersion index
The determination of size, zeta potential and polydispersion
index (PdI) of nanoparticles was performed on freshly prepared
samples. Size and PdI were measured by dynamic light scattering
and zeta potential was  measured by laser Doppler anemometry,
using a Zetasizer Nano ZS (Malvern instruments, UK). To prepare
the samples, 20 L of each formulation were diluted in 1 mL of
ultrapure water.
2.7.2. Production yield
To determine the production yield of nanoparticles, their prepa-
ration was  performed as previously described but without the use
of the 10 L of glycerol. After discarding the supernatant of each
formulation, the pellets were frozen and then dried on a freeze-
dryer (Alpha RVC, Germany). The yield of nanoparticle production
(PY) was calculated as follows:
PY = (Nanoparticle sediment weight/Total solids weight) × 100
(1)
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Table  1
Physicochemical characteristics and production yield of CS/LBGS unloaded nanoparticles (mean ± SD; n ≥ 3). Different letters represent significant differences in each
parameter (P < 0.05).
CS/LBGS (w/w) Size (nm) PdI Zeta potential (mV) Production yield (%)
1:1 174.8 ± 13.1 a 0.10 ± 0.01 +13.0 ± 2.7 b 9.1 ± 5.0 c
1:1.25 183.0 ± 4.7 a 0.10 ± 0.03 +14.5 ± 1.3 b n.d.
1:1.5  184.0 ± 4.1 a 0.09 ± 0.01 +13.0 ± 0.8 b 12.5 ± 3.9 c
1:1.75 182.5 ± 5.0 a 0.09 ± 0.01 +13.3 ± 1.0 b n.d.
1:2  183.0 ± 6.1 a 0.13 ± 0.02 +13.5 ± 0.6 b 30.2 ± 2.8 d
1:3 198.0 ± 26.0 a 0.12 ± 0.01 +13.0 ± 1.0 b n.d.
1:3.25  pp – – –




































1:4  pp – 
S: ultrapure chitosan; LBGS: sulfated locust bean gum; n.d.: not determined; PdI: 
here nanoparticle sediment weight is the weight after freeze-
rying and total solids weight is the total amount of solids initially
dded for nanoparticle formation.
.7.3. Morphological analysis
The morphological examination of CS/LBGS nanoparticles was
onducted by transmission electron microscopy (TEM; JEM-1011,
EOL, Japan). The samples were stained with 2% (w/v) phospho-
ungstic acid and placed on copper grids with carbon films (Ted
ella, USA) for TEM observation.
.8. Determination of antigen association efficiency
The amounts of HE and OVA encapsulated in nanoparticles were
etermined in each sample using the Micro BCA Protein Assay Kit
Pierce, USA). Different calibration curves were performed for each
ormulation (NP-HE or NP-OVA) using ultrapure water as solvent.
upernatants obtained upon centrifugation of the nanoparticle pro-
uction media were incubated with the MicroBCA reagent (2 h,
7 ◦C) in a 96-well plate. After that time, samples were analysed
y spectrophotometry (Infinite M200 Tecan, Austria) at 562 nm.
he supernatants of unloaded nanoparticles were used for blank
orrection.
The antigen association efficiency (AE) and loading capacity (LC)
ere calculated as follows:
AE(%) = [(Total antigen amount − Free antigen amount)/Total antigen amount]
×  100 (2)
C(%) = [Total antigen amount − Free antigen amount/Nanoparticle weight] × 100
(3)
.9. Evaluation of the structural integrity and antigenicity of the
oaded antigens
The integrity of HE and OVA antigens upon association to
anoparticles was confirmed using SDS-PAGE and immunoblotting
nalysis. Pellets of fresh antigen-loaded nanoparticles (NP-HE and
P-OVA) and free antigens (HE and OVA) were dispersed in elec-
rophoresis sample buffer (XT sample buffer) at a concentration of
 mg/mL. The mixtures were left in ultrasound bath for 15 min  and
hen heated at 100 ◦C for 10 min. After centrifugation (16,000 × g,
0 min, 15 ◦C) the supernatants were collected and heated at 100 ◦C
or 10 min. Immunoblotting were performed by using sera from pool of mice experimentally immunized subcutaneously with
ither HE (40 g) or OVA (20 g). After SDS-PAGE, the gel was
ransferred to a nitrocellulose membrane (pore size of 0.45 mm;
hatman
®
, UK) by using a semidry electroblotter (Bio-Rad, USA)– –
spersity index; pp: precipitate.
at 200 mA for 30 min, in transfer buffer (0.2 M glycine; 24 mM  Tris;
20% methanol, pH 8.3). The blot was placed in blocking buffer (3%
skimmed milk PBS) overnight at 4 ◦C. After washing with PBS-
Tween (PBS-T) the blot was  incubated with serum diluted 1:100
in PBS-T with 1% (w/v) skimmed milk for 3 h. After washing with
PBS-T, the blot was  incubated for 1 h at room temperature with the
peroxidase-conjugated goat anti-mouse IgG1 (Nordic Immunol-
ogy) diluted 1:100 in PBS-T with 1% (w/v) BSA. The blot was washed
with PBS-T and developed by incubation in a solution containing
H2O2 and 4-chloro-1-naphtol for 3 min  in the dark.
The apparent molecular masses of the proteins present in
both antigens were determined by comparing their electrophoretic
mobility with that of molecular mass markers.
2.10. In vitro release in SGF and SIF
HE and OVA release profiles from CS/LBGS 1:2 (w/w)  nanoparti-
cles loaded with 8% antigen were determined in simulated gastric
fluid (SGF) and simulated intestinal fluid (SIF) [26]. In these stud-
ies, 2.5 mg  of NP-HE and 7.02 mg  of NP-OVA were incubated in
SGF or SIF (37 ◦C, 100 rpm). At appropriate time intervals sam-
ples were collected, centrifuged (16,000 × g, 10 min, 15 ◦C) and the
released HE or OVA determined by the micro BCA (Pierce, USA)
assay. Unloaded nanoparticles were submitted to the same condi-
tions and used as blank. All experiments were performed at least
in triplicate (n ≥ 3).
2.11. Safety evaluation of unloaded nanoparticles
The in vitro cell viability and cytotoxicity of CS/LBGS nanoparti-
cles, as well as that of the raw materials involved in nanoparticle
production, was  assessed by the metabolic assay MTT  and the LDH
release assay, respectively.
The cells were seeded at a density of 1 × 104 cells/well in 96-
well microplates, in 100 L of the same medium used for culture in
flasks, and were incubated at 37 ◦C in 5% CO2 atmosphere for 24 h
before use. The effect on cell viability induced by three different
concentrations (0.1, 0.5 and 1.0 mg/mL) of unloaded nanoparticles,
and raw materials involved in nanoparticle production, was  eval-
uated over 3 h and 24 h. A SDS solution (2%, w/v) was  used as a
positive control of cell death, while cells incubated with DMEM
served as negative control. An additional control (DMEM + H2O)
consisting in a mixture of DMEM and H2O in the same ratio used
for the samples was used, in order to evaluate the contribution of
materials on cell viability. All formulations and controls were pre-
pared as solution/suspensions in pre-warmed cell culture medium
without FBS immediately before application to the cells.Briefly, culture medium of 24 h-old cells was replaced by fresh
medium without FBS containing the test samples or controls. A
constant ratio (3:1) between the culture medium and the solu-
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xposure, samples/controls were removed and 30 L of the MTT
olution (0.5 mg/mL  in PBS, pH 7.4) added to each well. After 2 h,
ny generated formazan crystals were solubilised with 50 L of
MSO. Upon complete solubilisation of the crystals, the absorbance
f each well was measured by spectrophotometry (Infinite M200,
ecan, Austria) at 540 nm and corrected for background absorbance
t 650 nm [27].
The assay was performed at least for three times with six repli-
ates at each concentration of test substance.
Considering the mild effect observed in the MTT  assay, the LDH
elease assay was performed on polymeric solutions and nanoparti-
le suspensions, after 24 h exposure to a concentration of 1.0 mg/mL
28]. Briefly, samples from the culture medium in the seeding plates
ere centrifuged (16,000 × g, 5 min, 15 ◦C), and reacted with the
DH release reagent at room temperature and protected from light.
he reaction was stopped after 30 min  by adding 15 L HCl 1N.
bsorbance was measured by spectrophotometry at 490 nm with
ackground correction at 690 nm.  The relative LDH release (%) was
alculated considering 100% release for samples incubated with
he lysis solution (positive control of cell death) The assay was
erformed at least three times with three replicates in each exper-
ment.
.12. In vivo evaluation of the immune response in BALB/c mice
Four groups of six female BALB/c mice were established for
he study with NP-OVA. The groups were immunized orally with
00 L of: 100 g of OVA, 100 g of OVA encapsulated in NP (NP-
VA); and subcutaneously with 50 L of: 20 g of OVA, 20 g
f OVA encapsulated in NP (NP-OVA). Blood and fecal samples
ere collected at weeks 0, 1, 2, 4 and 6 post immunization. The
ecal pellets were vortexed in PBS with 3% (w/v) of skimmed milk
100 mg/mL) before centrifugation, and then treated with a pro-
ease inhibitor cocktail to avoid immunoglobulin degradation.
Specific antibodies (IgG1 and IgG2a from sera; IgA from feces)
gainst OVA were determined by ELISA using 96 microtiter plates
Nunc MaxiSorp, Thermo Scientific). For that purpose, wells were
oated overnight with 1 g/mL of OVA in PBS at 4 ◦C and then
locked with 1% (w/v) BSA (sera samples) or 3% (w/v) skimmed milk
n PBS–T for 1 h at room temperature (fecal samples). After washing
ith PBS-T, a pool of samples was added in twofold serial dilutions
n PBS-T starting with 1:40, and incubated at 37 ◦C, for 4 h (serum);
r starting with 1:1 and incubated overnight at 4 ◦C (feces). Then,
ashed wells were incubated for 1 h at room temperature with
eroxidase-conjugated goat antibodies anti-mouse IgG1, IgG2a or
gA. For the color development, the substrate-chromogen used
as H2O2-ABTS and after 15 min  (serum) or 30 min  (feces) the
bsorbance was determined at max 405 nm.  The end titers were
etermined as the dilution of sample giving the mean O.D. ≥ 0.2
he obtained from untreated mice sera.
.13. Statistical analyses
The t-test and the one-way analysis of variance (ANOVA)
ith the pair wise multiple comparison procedures (Holm-Sidak
ethod) were performed to compare two or multiple groups,
espectively. All analyses were run using the SigmaStat statistical
rogram (Version 3.5, SyStat, USA) and differences were considered
o be significant at a level of P < 0.05.
. Results and discussion.1. Characterization of unloaded CS/LBGS nanoparticles
Several formulations of LBG-based nanoparticles were produced
y a very mild polyelectrolyte complexation, a process that involvesal Macromolecules 96 (2017) 786–797
electrostatic interaction between oppositely charged groups. This
procedure takes the advantage of occurring in a hydrophilic envi-
ronment with mild preparation conditions, avoiding the use of
organic solvents or high shear forces that might compromise the
stability of encapsulated materials [29,30]. LBG is a natural polymer
with neutral charge, which hinders the application of the men-
tioned methodology to directly produce nanoparticles. In order to
overcome that relevant limitation, a sulfate derivative of LBG (LBGS)
was produced, exhibiting a negative charge. The derivative was
determined to have a C:S molar ratio of 26.76, to which corresponds
a degree of substitution of 1.22, 0.24 charges per monomer and a
mean molar mass of 932 g/mol for the monomer. An Mw of 27 kDa
was determined by GPC analysis. Nanoparticles were obtained by
complexing LBGS with chitosan (CS). The latter is reported to have
a degree of deacetylation of 86%, to which correspond 0.86 positive
charges per monomer, and a Mw of 113 kDa [31]. The mean molar
mass for the monomer (198 g/mol) may  be obtained by ponderation
of the molar masses of the acetylated and deacetylated units.
Considering the pH of the involved solutions (4.3 for CS and
5.6 for LBGS), the polymers display positive and negative charges,
respectively. When CS and LBGS solutions are mixed, an electro-
static interaction is established between the negatively charged
sulfate groups of LBGS and the positively charged amino groups
of CS, leading to nanoparticle formation.
As the aim of this work was  to disclose the effect of LBGS in the
production of nanoparticles, the produced formulations accounted
with a similar or higher amount of this polymer comparing with CS.
Nine formulations of CS/LBGS nanoparticles were produced with
polymeric mass ratios varying within 1:1 and 1:4. After the prepara-
tion procedures, nanoparticles were characterized in terms of size,
polydispersion index (PdI), zeta potential and production yield. The
detailed results are shown in Table 1.
Formulations with a higher amount of LBGS (ratios ≥ 1:3.25,
w/w) resulted in precipitation. Considering that a constant amount
of CS is used to produce all the formulations, the observed pre-
cipitation is possibly due to the presence of an excess of anionic
charges, which neutralize CS positive charges and, thus, reduce or
eliminate electrostatic repulsion, leading to precipitation. For all
the other tested mass ratios, a clear Tyndall effect was  observed
upon mixing the two polysaccharides, indicating the presence of
colloidal particles. Nanoparticles were thus successfully obtained
for mass ratios varying between 1:1 and 1:3. Surprisingly, the size
of the particles did not present significant variations among the
tested ratios, being in all cases approximately 180 nm.  The ratio 1:3
resulted in nanoparticles with an average size of 198 nm,  but the
standard deviation increased 4–5 times (26 nm), which suggests
the beginning of the destabilization of the process of nanoparti-
cle formation, which is reinforced by the precipitation occurred in
the following ratio (1:3.25, w/w). The absence of variations was
not expected, as varying the amount of one of the polymers, and
therefore the amount of charges, should result in different nanopar-
ticle characteristics. The nanoparticles evidenced a very narrow
PdI (around 0.1) and a positive zeta potential around +13 mV.  As
observed for the size, it was  also unexpected that the zeta poten-
tial did not vary with the alteration of the mass ratios. This effect
is better analyzed considering the charge ratios involved in each
formulation. By dividing the charge of each repeating unit by its
molar mass, a charge per mass ratio is obtained for each polymer.
In a 1/n  formulation of CS/LBGS, the −/+ charge ratio is calculated
by:
−/ + charge ratio = n.charge per mass (LBGS)/charge per mass (CS) (4)The charge ratio was observed to vary between 0.30 and 0.91
without significant effect on the resulting zeta potential (CS/LBGS
nanoparticles 1:1 to 1:3; w/w). However, on reaching −/+ charge
ratios of 0.98, 1.06 and 1.21 precipitation occurred (CS/LBGS
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anoparticles 1:3.25 to 1:4; w/w). Although this behavior was
nexpected, it has been reported in other works regarding polysac-
haride nanoparticles produced by the same methodology [32–36].
It was previously demonstrated that the process leading to the
ssembly of polyelectrolyte complexes has two major steps: the
apid formation of molecular or primary complex particles, and a
ubsequent phase corresponding to the aggregation of primary par-
icles to secondary particles. While the primary particles are held
ogether by long-range electrostatic interactions, the formation of
econdary particles involves short-range dispersive interactions
37,38]. In this case, considering the differences between the charge
ensities of the two polysaccharides (0.86 charges/monomer in
S and 0.24 charges/monomer in LBGS), a very inefficient charge
airing should be expected. Therefore, and also regarding the
ifferences in the molecular weights of the polysaccharides, in
ormulations 1:1 to 1:1.5, a reduced number of primary com-
lexes should form. The poor charge neutralization should result in
nhanced electrostatic repulsion between primary particles, lead-
ng to low dispersive attraction and smaller particle sizes, as well
s to low yields. By increasing the amount of LBGS, towards the
:2 formulation, a larger number of primary particles form, which
hould tend to aggregate in larger particles as the (−/+) charge
atio increases to 0.60. However, that was not the case, with all for-
ulations presenting almost invariant particle sizes, which should
ean that more particles formed; thus, the slight increase in yield
bserved in the latter formulation [38]. The fact that all formu-
ations present similar surface potentials of ∼13 mV,  seems to
orroborate this hypothesis, as this potential should correspond to a
epulsive electrostatic force overcoming the dispersive interactions
nd, therefore, preventing the particles from growing further. This
ehavior was observed in other works [33], normally associated
o the use of ultrapure CS. Therefore, another possible explanation
ay  reside in conformational features of CS when the free base
orm is dissolved in acetic acid or when the hydrochloride salt is
issolved in water.
Taking into account the previous observations regarding the
imilarity of physicochemical characteristics and the suggested
estabilization starting in formulation CS/LBGS 1:3 (w/w), it was
ecided to determine the production yield of nanoparticles 1:1,
:1.5 and 1:2 (w/w). While no significant differences were observed
etween the first two, with yields of 9–13%, the latter registered a
uch higher yield around 30% (P < 0.05). This is the trend that is
sually observed [32,39–41] and reflects the fact that, up to a cer-
ain limit, when increased amounts of LBGS are incorporated, the
ccurrence of electrostatic interactions is also increased, resulting
n the formation of a higher number of nanoparticles [42].
In order to restrict the number of formulations for the subse-
uent tasks, and considering that the production yield was the most
ifferentiating characteristic of the nanoparticles, it was decided
o select the formulations CS/LBGS 1:1.5 and 1:2 (w/w)  for the
est of the studies. Fig. 2 displays the morphological character-
zation of representative nanoparticles (CS/LBGS 1:2, w/w).  This
as performed by TEM and revealed a solid and compact structure,
howing a tendency to exhibit a spherical-like shape.
.2. Characterization of antigen-loaded nanoparticles
Bearing in mind the objective of using CS/LBGS nanoparticles
n oral vaccination, the first approach regarding the association
f an antigen relied on using an immunogenic acellular extract
btained from Salmonella Enteritidis cells (HE), which is a particu-
ate liposome-like antigenic complex [20,43]. After performing the
n vivo studies, which results are reported later on, the need to test
oluble antigens was identified, in order to permit a clearer evalua-
ion of the real adjuvant properties of the formulated nanoparticles.
herefore, in a second stage of the experiments, the soluble proteinFig. 2. TEM microphotograph of CS/LBGS 1:2 (w/w) nanoparticles.
ovalbumin (OVA) was  associated as model antigen. Additionally,
as being one of the mostly used molecules for the antigen effect,
it enables further comparisons with the literature. As pertinent
information, the HE extracts are mainly composed of proteins
(29%) and lipopolysaccharides (LPS, 59%) [21]. In this context, it is
well reported in the literature that LPS fractions have great ability
to generate immunological responses, since they are prototypical
pathogen-associated molecular patterns (PAMP’s) [44]. Therefore,
taking into account that OVA is a protein devoid of PAMP compo-
nents, it is assumed as less immunogenic than the LPS-containing
HE.
3.2.1. Salmonella Enteritidis extract-loaded CS/LBGS
nanoparticles
The first demonstration of the usefulness of the developed
nanoparticles to act as adjuvants in a vaccination strategy relies
on the determination of their ability to associate antigens. In order
to verify this, different amounts of the bacterial HE antigens were
associated to nanoparticles CS/LBGS 1:1.5 and 1:2 (w/w). Depart-
ing from initial concentrations of 2%, 4% and 8% (w/w) of the
total amount of the polymers, an effective and similar association
was observed in all cases. In fact, the association efficiency varied
within 29–36% (Table 2), independently of both the initial concen-
tration of antigen and the formulation. These resulted in loading
capacities up to 12%. Taking into account that HE is negatively
charged when in the LBGS-HE solution, and also considering the
high density of free amino groups present in the chitosan solution,
it could be assumed that the main factor affecting HE associa-
tion to the nanoparticles was  an electrostatic interaction. This is
in agreement with many other works reporting the association of
protein-based macromolecules to nanoparticles produced by poly-
electrolyte complexation [42,45–47]. In turn, although it could be
expected that HE and LBGS might compete in their interaction with
chitosan, the obtained results do not show an influence of LBGS con-
tent on HE association. This may  be due to the fact that LBGS could
also interact with HE by means of hydrophobic interactions, hydro-
gen bonding and other intermolecular forces [39]. The absence of a
concentration-dependent effect regarding HE was also unexpected,
although it has been observed in other works [41,42].
Table 2 further displays the physicochemical characteristics of
HE-loaded CS/LBGS nanoparticles. The size of the particles was
around 190–200 nm independently of the specific formulation and
the amount of HE associated. When comparing with the corre-
sponding unloaded nanoparticles, which had a size of 183–184 nm,
no significant differences were generally observed. An exception
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Table 2
Physicochemical characteristics, production yield and association efficiency of HE antigens in CS/LBGS nanoparticles (mean ± SD; n ≥ 3). Different letters represent significant
differences in each parameter, evaluated separately for each mass ratio (P < 0.05).
CS/LBGS (w/w) HE (%) Size (nm) PdI Zeta potential (mV) Production yield (%) Association efficiency (%) Loading capacity (%)
1:1.5 0 184.0 ± 4.1 a 0.09 ± 0.01 +13.0 ± 0. e 12.5 ± 3.9 i – –
2  191.5 ± 7.8 a 0.11 ± 0.02 +10.0 ± 1.4 f 9.6 ± 6.3 i 31.2 ± 7.4 k 6.4 ± 1. m
4 190.0 ± 11.3 a 0.10 ± 0.01 +10.0 ± 1.4 f 13.1 ± 3.8 i 29.0 ± 2.6 k 8.5 ± 0. m
8 196.5 ± 2.1 b 0.08 ± 0.01 +9.5 ± 0.7 f 15.5 ± 0.0 i 25.3 ± 3.2 k 12.1 ± 1.5 n
1:2 0 183.0 ± 6.1 c 0.13 ± 0.02 +13.5 ± 0. g 30.2 ± 2.8 j – –
2  192.0 ± 9.9 c 0.11 ± 0.00 +10.5 ± 0.7 h 28.5 ± 5.2 j 35.5 ± 9.7 l 2.4 ± 0.7 o


















































8 202.5 ± 10.6 d 0.13 ± 0.03 +12.5 ± 0. g
S: ultrapure chitosan; HE: antigenic extract from Salmonella Enteritidis; LBGS: sul
as only observed when 8% HE was associated, for both formula-
ions, with sizes reaching approximately 200 nm (P < 0.05), but this
bservation is considered to be devoid of physiological relevance.
he PdI of the nanoparticles remained remarkably low after associ-
tion of HE (around 0.1) and a very slight decrease of 2–3 mV in zeta
otential was generally observed (P < 0.05). Regarding the latter,
he only exception was for the formulation 1:2, again when 8% HE
as associated (zeta potential of +12.5 mV), in which no significant
ariation was observed comparing with the equivalent unloaded
anoparticles. Regarding the yield of the process of nanoparticle
roduction, it was also observed an absence of effect upon asso-
iation of HE antigens, independently of the used concentration.
onsidering that size and zeta potential values remained approxi-
ately similar after the association of the antigen, the maintenance
f the production yield is indicative of displacement of the polymers
o permit the incorporation of the active molecule.
Taking into account the properties exhibited by HE-loaded
anoparticles, it was decided to select the formulation CS/LBGS 1:2
ith 8% of HE, to perform subsequent studies. This selection was
riven by the presence of a higher theoretical amount of LBG and
E antigens. The morphological examination of this specific for-
ulation was performed by TEM and revealed the maintenance
f the solid and compact structure of the unloaded nanoparticles,
lso showing a tendency to exhibit a spherical-like shape (data not
hown).
As shown in Table 2, the developed HE-loaded CS/LBGS
anoparticles evidence adequate physicochemical properties for
he objective of oral delivery aimed at mucosal vaccination, with a
ize around 200 nm and a positive zeta potential. In fact, the size
s small enough to permit an intimate contact with epithelial sur-
aces, which is maximal at 50–500 nm [48,49]. In turn, the positive
eta potential further potentiates the interaction with epithelia, as
his is negatively charged and, thus, an electrostatic interaction is
nabled. In summary, these characteristics are expected to provide
 prolonged retention of nanoparticles close to epithelial surfaces,
otentiating the uptake by M cells and/or antigen release. The pres-
nce of chitosan is expected to further contribute to this effect,
wing to its known mucoadhesive ability [50].
.2.2. Ovalbumin-loaded CS/LBGS nanoparticles
As mentioned above, the need to associate a second antigen
as identified and OVA was selected for this end. Considering
hat CS/LBGS nanoparticles 1:2 (w/w) containing 8% HE had been
reviously selected for further studies, the production of OVA-
oaded nanoparticles respected the same composition, in order to
ffectively evaluate the particle contribution as vaccination adju-
ant. As stated in Table 3, OVA was successfully encapsulated with
 similar efficiency as that for HE (26.4%), which resulted in a
oading of 5.2%. Regarding the physicochemical characteristics of
VA-loaded nanoparticles, there are no statistically significant dif-
erences in size when comparing with unloaded particles, while
 slight decrease of zeta potential around 4 mV  was  observed30.1 ± 3.7 j 31.9 ± 4.0 l 7.8 ± 1.0 q
ocust bean gum; PdI: polydispersity index.
(P < 0.05). The production yield registered a significant increase
from 30% to 38% (P < 0.05). When a comparison with HE-loaded
nanoparticles is performed, considering the corresponding formu-
lation, it should be highlighted that OVA-loaded nanoparticles have
a significantly lower size (179 nm vs 203 nm)  and higher produc-
tion yield (38% vs 30%) (P < 0.05). A significant difference was also
found for zeta potential, although this only decreased around 3 mV
(P < 0.05).
Naturally, the literature does not report similar nanoparticles, as
LBG is being proposed for the first time herein, but chitosan-based
nanoparticles have been suggested many times regarding oral vac-
cination [51–58]. Occasionally, ovalbumin was  the tested antigen
[53], resulting in nanoparticle size around 300 nm and a strong
positive zeta potential (+43 mV). As said above, the positive zeta
potential is a desirable characteristic to mediate and favor the inter-
action with the epithelium. In our work, the proposed nanoparticles
present a lower zeta potential, but also a lower size, which further
benefits this interaction, due to an increased surface area.
3.3. Evaluation of the structural integrity and antigenicity of the
loaded antigens
As detailed above, the association of either HE or OVA into
nanoparticles was  performed by means of a mild ionic interac-
tion. Along with the determination of the ability of the developed
nanoparticles to associate the selected antigens, it is also of utmost
importance to ensure that the particles and the procedure used for
their production enable the preservation of the structural integrity
and antigenicity of the encapsulated molecules. SDS-PAGE analysis
followed by immunoblotting was  the method used to perform this
evaluation.
The obtained results are depicted in Fig. 3a–d, for HE and OVA,
respectively. Regarding HE, SDS-PAGE results shown in Fig. 3a
demonstrate that the procedure used for HE entrapment did not
affect the structural integrity of the molecules, as no additional frag-
ments are observed in the HE released from nanoparticles (lane 2)
when compared with the control HE dispersion (lane 1).
Moreover, the immunoblot shown that the HE-specific antibod-
ies recognized the epitopes in a similar way as for the free HE
dispersion (Fig. 3b). This confirms that the antigenicity of HE was
not altered after the entrapment into the nanoparticles.
Concerning the association of OVA, similar results were
observed. As demonstrated in Fig. 3, the SDS-PAGE of OVA
released from nanoparticles (Fig. 3c) showed identical bands for
the entrapped (lane 2) and free OVA (lane 1). Furthermore, there
were no additional bands indicating the presence of aggregates or
fragments greater or less than 45 kDa (molecular weight of OVA).
Hence, the data suggest that the structural integrity of OVA was
not significantly affected by the entrapment procedure. The anti-
genicity of OVA was also not modified after association, as the
immunoblot bands from OVA solution (Fig. 3d, lane 1) and OVA
released from nanoparticles (Fig. 3d, lane 2) were identical.
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Table  3
Physicochemical characteristics, production yield and association efficiency of OVA in CS/LBGS nanoparticles (mean ± SD; n ≥ 3). Different letters represent significant
differences in each parameter (P < 0.05).
CS/LBGS (w/w) OVA (%) Size (nm) PdI Zeta potential (mV) Production yield (%) Association efficiency (%) Loading capacity (%)
1:2 0 183.0 ± 6.1 a 0.13 ± 0.02 +13.5 ± 0.6 b 30.2 ± 2.8 d – –
8  178.6 ± 6.8 a 0.13 ± 0.02 +9.0 ± 1.0 c 37.9 ± 4.1 e 26.4 ± 3.8 5.2 ± 0.7
CS: ultrapure chitosan; LBGS: sulfated locust bean gum; OVA: ovalbumin; PdI: polydispersity index.
















































OVA in SIFig. 3. SDS-PAGE (a, c) and immunoblotting (b, d) analysis of the antigens used, HE
ere  performed with specific antibodies against HE or OVA, respectively; PS: prote
Altogether, these results indicate the adequacy of polyelec-
rolyte complexation as a method to produce antigen-loaded
olymeric nanoparticles, reinforcing results already available in
he literature. In fact, several works reporting the preparation of
anoparticles using methodologies involving electrostatic inter-
ction and using materials such as chitosan, its derivatives and
lginate, have demonstrated to provide protection to various model
ntigens including inactivated influenza virus [59], bovine serum
lbumin [60], tetanus toxoid [61] and diphtheria toxoid [62].
.4. In vitro release in SGF and SIF
Considering an application in oral vaccination, it is adequate to
etermine the release of the encapsulated antigens in media sim-
lating both the gastric (SGF) and intestinal (SIF) environments. In
he proposed approach it is important that the nanoparticles not
nly provide protection to the antigens regarding the harsh condi-
ions of the gastric medium, but also prevent their release, in order
o maximize the antigen internalization by the M cells mediated by
he particle.
Fig. 4 shows the release profile of HE and OVA in SGF and SIF. As
an be observed, HE is considered to not present significant release
n any of the tested media. In fact, in SGF it releases a maximum
mount of 7.5% in 2 h, while releasing 4.3% in SIF after 4 h. Moreover,
lthough it might not be relevant from a physiological point of view,
E release at the end of 24 h was 21.6% ± 2.0 and 13.2% ± 4.8 in
GF and SIF, respectively. In turn, OVA presented a rather different
ehavior. In this case, the release in SGF was of 45.0% at the end of
 h, and 3.0% in SIF at the end of 4 h.Fig. 4. Antigen released overtime from CS/LBGS nanoparticles in simulated gastric
fluid (SGF) and simulated intestinal fluid (SIF), at 37 ◦C (mean ± SD; n ≥ 3).
Considering what was  stated above, in the case of OVA-loaded
nanoparticles, it could be assumed that a high amount of encapsu-
lated OVA releases in the harsh conditions of gastric environment,
affecting the biological activity of the molecule. This difference
observed for HE-loaded and OVA-loaded nanoparticles could be
hypothetically explained by a greater association of HE into the
particle, contrasting with a substantial adsorption of OVA onto its
surface. Although the determined physicochemical properties do
not confirm these effects, it should be reminded that a very small
amount of protein is being associated (theoretical load of 8% (w/w)).
OVA release at the end of 24 h was 75.5% ± 13.1 and 9.8% ± 1.5 in SGF
and SIF, respectively. It is remarkable that an insignificant amount




































































one of the most used polymers in drug delivery, nanocarriers other
than nanoparticles have been proposed, such as nanocapsules and

















ig. 5. Caco-2 cell viability measured by the MTT  assay after 24 h exposure to inc
S/LBGS  nanoparticles (NP). Data represent mean ± SEM (n ≥ 3, six replicates per e
MEM.
f antigen was observed to be released in SIF in both cases. This
eans that a great amount of antigen remains associated to the
anoparticles until they reach the contact with the Peyer patches,
here the nanoparticles are expected to have a favored contact
ith the M cells, which will potentiate the immunological response.
Salman et al. studied the HE release from Gantrez
®
AN nanopar-
icles, registering 10% release in SGF (after 30 min) and 12% in
IF (after 3 h) [63], values slightly higher than those obtained in
ur study. In turn, Garinot et al. studied the release of OVA from
oly(d,l-lactide-co-glycolide) (PLGA) nanoparticles [3]. Pegylated
LGA-based nanoparticles which were surface decorated with RGD
olecules to target M cells (OVA association efficiency of 30–50%)
egistered 5% release after 2 h of incubation in gastric medium (HCl
.1 M)  and 10–20% in intestinal medium. PLGA-lipid nanoparticles
onjugated with ulex europaeus agglutinin-1 and containing the
oll-like receptor agonist monophosphoryl lipid A (95% OVA associ-
tion efficiency), released 17% of the protein after 2 h incubation in
astric acid medium (0.1 M HCl) and 3 h in intestinal medium (PBS
H 6.8) [64]. Comparatively, our work registered higher release of
his protein after cumulative contact with the two  media, but we
xpect that the remaining amount suffices for an adequate immu-
ization effect.
While no studies report the release of OVA as model antigen
rom chitosan nanoparticles proposed for oral immunization, there
re some works on chitosan-based microparticles. The results are
owever uneven, certainly as a result of different methods of prepa-
ation of microparticles and the use of diverse chitosan molecules.
n fact, different works reported either immediate release of OVA
n SGF [65], or only 50% in 2 h [66]. The latter behavior is similar to
hat registered in our work, where 45% released in 2 h. The results
egarding the release in SIF or PBS pH 7.3 were more coincident,
here a maximum release of 10%–20% was determined after 1 h
4,65,66]. This is not far from the 3% registered in our work at the
nd of 4 h.
.5. Safety evaluation of unloaded nanoparticles
Caco-2 cells were used to evaluate the safety profile of CS, LBGS
nd CS/LBGS nanoparticles by means of the metabolic assay MTT
nd the membrane integrity test based on LDH release. Samples
ere tested at 3 h and 24 h, at concentrations between 0.1 and
 mg/mL. The overall observation of the results reveals a mild effect
n cell viability from both the polymers and nanoparticles, con-
idered to be devoid of biological relevance. At 3 h cell viability
emained above 88% in all cases (data not shown). Prolonging the
xposure until 24 h resulted in slight alterations (Fig. 5), althoughg concentrations of Chitosan (CS), sulfate Locust Bean Gum  (LBGS) derivative and
ment at each concentration). Dashed line indicates 70%. * P < 0.05 compared with
cell viability remained above 70% for all samples and concentra-
tions. This value is that considered by ISO 10993-5 [67] as the level
below which a toxic effect occurs. The only observation deserving
a mention is that the exposure to the highest concentration tested
(1.0 mg/mL) of CS decreased cell viability to around 70% (P < 0.05),
but nanoparticles shown 90% at the same concentration.
A control was used that consists in a mixture of DMEM and
H2O in the same ratio used for the samples, taking into account
that both the raw materials and the nanoparticles were solubi-
lized/suspended in water and diluted with cell culture medium
prior to incubation with the cells. This enables a real evaluation
on the contribution of these materials on the final cell viability.
As observed in Fig. 5, the cell viability induced by this control was
72% when tested at 24 h, similar to that of 1.0 mg/mL  of CS (71%).
Remarkably, focusing on the concentration of 1.0 mg/mL, the cell
viability obtained by exposure to the nanoparticles was higher
than that registered for CS assessed individually and the control
of DMEM + H2O (P < 0.05).
LBG-based nanoparticles are now being reported for the first
time. Therefore, the literature does not report any informa-
tion regarding the cytotoxic effect of the particles, hindering
the establishment of any comparison. In contrast, chitosan-based
nanoparticles have been reported for a long time. As chitosan isFig. 6. Caco-2 cell viability measured by the LDH release assay after 24 h exposure
to  1 mg/mL  solutions of Chitosan (CS), sulfate Locust Bean Gum (LBGS) derivative
and CS/LBGS nanoparticles (NP). Data represent mean ± SEM (n ≥ 3, three replicates
per  experiment). * P < 0.05 compared with DMEM.












































































































Fig. 7. Immunogenicity of OVA after oral administration in mice. Serum anti-OVA
A)  IgG1; B) IgG2a and C) faecal anti-OVA IgA response in BALB/c mice (n = 6) after
oral  immunization with 100 g of OVA solution (OVA) or 100 g of encapsulated
OVA (NP-OVA). Antibody titers were determined in pooled serum samples at daysL. Braz et al. / International Journal of B
30], but even when similar carriers are at play, it is frequently
ifficult to establish valid comparisons taking into account the
arge variety of chitosan molecules (chitosan base/salt(s), molec-
lar weight, deacetylation degree, etc.) which is also known to
ave a role on cell viability [68]. Notwithstanding these limitations,
he general outcome regarding chitosan-based nanoparticles is a
ery mild effect on Caco-2 cell viability. Attempting to perform a
irect and accurate comparison, other works assessing a nanopar-
icle concentration of 1.0 mg/mL  reported similar results to those
ound in this work, both at 3 h [69] and 24 h [70,71].
The assay of LDH release complements the information provided
y the MTT. The loss of intracellular LDH and its release to the cul-
ure medium is an indicator of irreversible cell death due to cell
embrane damage [72,73]. The amount of LDH released by Caco-
 cells exposed to CS/LBGS nanoparticles was determined, using
s control both the incubation with cell culture medium (negative
ontrol of cell death) and the exposure to a lysis buffer (positive
ontrol of cell death, assumed as 100%). As observed in Fig. 6, the
xposure to the raw materials CS and LBGS induced the release of an
mount of LDH (around 25%) that is comparable to that of the nega-
ive control, as no statistically significant differences were detected.
n the contrary, the contact with CS/LBGS nanoparticles resulted in
n unexpected increased level of LDH release (43%; P < 0.05), which
s indicative of cytotoxicity.
If a direct correlation between LDH release and cell death is
ssumed, the contact with the nanoparticles results in approxi-
ately 60% cell viability, comparing with the 80% elicited by DMEM.
urprisingly, this does not correspond with the observations result-
ng from the MTT  assay, in which a cell viability of 90% was  observed
or this condition. One possible explanation is that these nanoparti-
les act as metabolic enhancers, thus although with a lower number
f available cells (as indicated by the LDH assay), MTT  conversion
nto formazan is accelerated, resulting in the overestimation of the
ell viability. This difference in the results of the two assays rein-
orces the need to perform various and different tests to conclude
n the safety profile of nanoparticles.
.6. In vivo evaluation of the immune response in BALB/c mice
After verifying the ability of LBG derivatives to produce nanopar-
icles with capacity to associate antigens of interest and evaluating
he cytotoxicity of the nanoparticles in an intestinal model, an in
ivo assay was designed and setup to evaluate the adjuvant effect
f the particles towards an immunization strategy.
A study was performed with HE-loaded CS/LBGS nanoparticles,
ut no differences were generally observed to a statistically sig-
ificant level when comparing the results elicited by free HE and
P-HE (data not shown). HE antigens are possibly too robust and
apable of inducing a strong immune response when administered
n free form, thus not potentiating the observation of an adjuvant
ffect by the nanoparticles. This fact may  be explained by the par-
iculate nature of HE (liposome-like), and the high content of LPS
n the HE extract. It is known that LPS is recognized by TLR-4 [74].
evertheless, long-term memory and challenge studies should be
erformed in order to verify whether NP-HE could improve the
mmunological response, in spite of a similar antibody-mediated
esponse. After this approach with HE, the need to test a second
ntigen was identified. The soluble antigen OVA was selected for
his effect, being administered in free and encapsulated form (NP-
VA), by oral and subcutaneous routes. Serum and feces from the
ice were collected before the immunization and at weeks 1–6
ost immunization. Unloaded nanoparticles were tested in the NP-
E assay and, as expected, were shown to not induce any type of
mmune response (data not shown).
Figs. 7 and 8 show the serum titers of IgG1 and IgG2a (systemic
esponse), and IgA (mucosal response) after an oral or subcu-0,  7, 14, 21 and 28 post-administration.
taneous immunization of mice by a single dose of OVA-loaded
nanoparticles or free OVA. Overall, it is observed the adjuvant effect
of nanoparticle formulations compared to free OVA in both routes.
Focusing on the oral immunization (Fig. 7), the elicited IgG1 spe-
cific response (Th2) was significant after OVA immunization, either
free or encapsulated. Nanoparticles did not improve the effect
of OVA regarding Th2 activation (IgG1, Fig. 7A), but, however, a
strong improvement was observed regarding Th1 activation (IgG2a,
Fig. 7B), as the respective area under the curve (AUC) was five times
higher than that determined for free OVA. Intestinal immune sys-
tem has a predisposition towards Th2 cell responses since antigen
presentation by DCs from PPs are characterized by the production
of IL-4, IL-6, and IL-10, which inhibit a Th1 response [75]. It is also
important to refer that soluble antigens usually elicit high levels
of IgG1 antibodies (Th2 response), but very low levels of IgG2a
(Th1 response) [76]. Therefore, under these circumstances, the role
of the adjuvant becomes critical in order to achieve a more bal-
anced Th1/Th2 response. A similar positive effect of association was

















































Fig. 8. Immunogenicity of OVA after S.C. administration in mice. Serum anti-OVA
A)  IgG1; B) IgG2a and C) faecal anti-OVA IgA response in BALB/c mice (n = 6) after
S.C. immunization with 20 g of OVA solution (OVA) or 20 g of encapsulated OVA


















level.4,  21 and 28 post-administration.
pparent regarding the mucosal response (IgA), as shown in Fig. 7C.
n this respect, OVA-loaded nanoparticles registered a 3-fold higher
UC when comparing with free OVA.
When considering the determined AUC, a comparable mucosal
esponse was elicited when the formulation was administered by
ubcutaneous route (Fig. 8C). However, the pattern registered for
he responses was markedly different. In fact, while the oral immu-
ization induced a response that was detected from week one,
he response obtained upon subcutaneous immunization was  only
bserved starting from week two to four. In turn, the subcutaneous
dministration of nanoencapsulated OVA showed a similar activa-
ion of Th2 (IgG1, Fig. 8A) and Th1 (IgG2a, Fig. 8B) to that described
or free OVA.
After oral immunization, OVA-loaded nanoparticles showed a
redominant Th2 response compared to the slightly elicited Th1
ne (AUCTh2 was seven times higher than AUCTh1), consistent with
esults obtained by others [53,77–80]. On the contrary, subcu-
aneous immunization with OVA-loaded nanoparticles elicited aal Macromolecules 96 (2017) 786–797
more balanced Th1 and Th2 response. In order to perform a semi-
quantitative comparison between the nanoparticle formulation
and the free OVA, the AUC of the titers representing the systemic
immune response (AUCTh1, AUCTh2) were measured and summed.
Regarding the oral immunization, an increase of 34% in the total
AUC was accounted for the encapsulated OVA. In turn, this associa-
tion only induced a 13% increase in the response after subcutaneous
immunization. This is possibly justified by the presence of man-
nose units in LBG nanoparticles, potentiating a stronger interaction
with M cells and the mediation of a stronger immune response
when the nanoparticles are administered by the oral route, as was
suggested in a study performed with mannosylated nanoparticles
[80,81]. In that work it was  verified that mannosylated nanopar-
ticles induced a more balanced Th1/Th2 response comparing with
non-mannosylated nanoparticles, an effect attributed to the high
tropism of mannosylated particles for uptake by PPs rich in APCs
[63].
The mucosal IgA antibodies obtained after oral immunization
with OVA-loaded nanoparticles were higher than after subcuta-
neous administration. This phenomenon may be related to the
effective uptake of nanoparticles by gut Peyer’s patches, obviously
only possible after oral delivery, and the passage of the particulate
system to lymphocytes causing an effective generation of mucosal
IgA. However, it should be taken into account that a 5-fold higher
dose of antigen was administered by oral route.
The described results indicate a significant adjuvant effect of
CS/LBGS nanoparticles. Both the presence of mannose units in LBG,
which target M cells and DC’s, and the mucoadhesive characteristics
of CS, are thought to have played a role in the improved response
mediated by nanoparticles. Additionally, results obtained by others
suggest that targeting to M cells and/or mucosal DCs should be the
way to achieve a better and/or more balanced immune response
[53,77–80]. It is worth to mention that the oral immunization per-
formed in these in vivo assays, truly evaluates the system capability,
since it was made by oral gavage (not intraduodenally) and no prior
administration of sodium bicarbonate solution, in order to neutral-
ize the acid environment of the stomach, was made. The role of M
cells and mucosal DCs to achieve the adjuvant properties suggested
herein should be demonstrated.
4. Conclusions
This work reports for the first time the production of nanopar-
ticles based on locust bean gum, demonstrating the ability of the
produced sulfate derivative of locust bean gum to form nanopar-
ticulate complexes with chitosan by means of an electrostatic
interaction. The produced nanoparticles were proposed as adju-
vants in oral immunization, efficiently associating two model
antigens (HE antigenic complex and OVA) without compromis-
ing their structural integrity. Displaying a size around 180–200 nm
and a positive zeta potential, the antigen-loaded nanoparticles
were deemed adequate for the proposed application in oral immu-
nization. The cytotoxic assessment performed in Caco-2 cells
revealed no alterations at the level of cell metabolic activity
upon exposure to the nanoparticles, but a mild negative effect on
cell membrane integrity was  observed. The in vivo proof of con-
cept demonstrated the adjuvant effect of the proposed system
when the soluble antigen OVA was  used as model. Addition-
ally and as expected, nanoparticles were capable of inducing not
only a systemic response, but also a response at the mucosalSumming up, CS/LBGS nanoparticles are promising as an anti-
gen delivery strategy. However, further experiments are required
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